BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70. [PMID: 9525364 DOI: 10.1016/S0140-6736(97)11443-X] [Cited by in Crossref: 422] [Cited by in F6Publishing: 434] [Article Influence: 16.9] [Reference Citation Analysis]
Number Citing Articles
1 Massongo M, Ngarka L, Balkissou DA, Poka-mayap V, Sonwa SV, Tatah GY, Nfor LN, Mengnjo MK, Chokoke E, Moutlen BPM, Perrig S, Pefura-yone EW, Njamnshi AK, Wali SO. Sleep Apnea Syndrome: Prevalence and Comorbidity with Other Non-communicable Diseases and HIV Infection, among Hospitalized Patients in Yaoundé, Cameroon. Sleep Disorders 2022;2022:1-8. [DOI: 10.1155/2022/4359294] [Reference Citation Analysis]
2 Sekhar RV. HIV-Associated Lipodystrophy and Lipoatrophy. Fundamentals of HIV Medicine 2021 2021. [DOI: 10.1093/med/9780197576595.003.0048] [Reference Citation Analysis]
3 Sebo ZL, Rendina-Ruedy E, Ables GP, Lindskog DM, Rodeheffer MS, Fazeli PK, Horowitz MC. Bone Marrow Adiposity: Basic and Clinical Implications. Endocr Rev 2019;40:1187-206. [PMID: 31127816 DOI: 10.1210/er.2018-00138] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 13.0] [Reference Citation Analysis]
4 Hudd TR, Chugh P, Zaiken K. A unique case of buffalo hump after prolonged use of spironolactone. J Am Pharm Assoc (2003) 2018;58:679-81. [PMID: 30219491 DOI: 10.1016/j.japh.2018.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Mcgee S. Cushing Syndrome. Evidence-Based Physical Diagnosis 2018. [DOI: 10.1016/b978-0-323-39276-1.00014-7] [Reference Citation Analysis]
6 Kobayashi N, Nakahara M, Oka M, Saeki K. Additional attention to combination antiretroviral therapy-related lipodystrophy. World J Virol 2017; 6(3): 49-52 [PMID: 28868242 DOI: 10.5501/wjv.v6.i3.49] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis 2017;17:551. [PMID: 28793863 DOI: 10.1186/s12879-017-2626-z] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 12.8] [Reference Citation Analysis]
8 Yalamanchi S, Brown T, Dobs A. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-18741-9_38] [Reference Citation Analysis]
9 Mokaya K, Maurer T. HIV/Opportunistic Infections. Clinical and Basic Immunodermatology 2017. [DOI: 10.1007/978-3-319-29785-9_20] [Reference Citation Analysis]
10 Yalamanchi S, Brown T, Dobs A. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2016. [DOI: 10.1007/978-3-319-20797-1_38-1] [Reference Citation Analysis]
11 HIV protease inhibitors. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.01693-0] [Reference Citation Analysis]
12 Leach LL, Bassett SH, Smithdorf G, Andrews BS, Travill AL. A Systematic Review of the Effects of Exercise Interventions on Body Composition in HIV+ Adults. Open AIDS J 2015;9:66-79. [PMID: 26587075 DOI: 10.2174/1874613601509010066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
13 Cereijo R, Gallego-Escuredo JM, Moure R, Villarroya J, Domingo JC, Fontdevila J, Martínez E, Gutiérrez Mdel M, Mateo MG, Giralt M, Domingo P, Villarroya F. The Molecular Signature of HIV-1-Associated Lipomatosis Reveals Differential Involvement of Brown and Beige/Brite Adipocyte Cell Lineages. PLoS One 2015;10:e0136571. [PMID: 26305325 DOI: 10.1371/journal.pone.0136571] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
14 Hejazi N, Rajikan R. Metabolic Abnormalities in HIV-Infected Populations without or with Antiretroviral Therapy (ART). Health of HIV Infected People 2015. [DOI: 10.1016/b978-0-12-800769-3.00002-0] [Reference Citation Analysis]
15 Agarwal N, Balasubramanyam A. Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr. Adipocyte 2015;4:55-9. [PMID: 26167403 DOI: 10.4161/adip.29852] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
16 Anand D, Puri S. Anthropometric and Nutritional Profile of People Living with HIV and AIDS in India: an Assessment. Indian J Community Med 2014;39:161-8. [PMID: 25136157 DOI: 10.4103/0970-0218.137153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
17 Rao MN, Chau A, Madden E, Inslicht S, Talbot L, Richards A, O'Donovan A, Ruoff L, Grunfeld C, Neylan TC. Hyperinsulinemic response to oral glucose challenge in individuals with posttraumatic stress disorder. Psychoneuroendocrinology 2014;49:171-81. [PMID: 25108160 DOI: 10.1016/j.psyneuen.2014.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
18 Aschbacher K, Kornfeld S, Picard M, Puterman E, Havel PJ, Stanhope K, Lustig RH, Epel E. Chronic stress increases vulnerability to diet-related abdominal fat, oxidative stress, and metabolic risk. Psychoneuroendocrinology 2014;46:14-22. [PMID: 24882154 DOI: 10.1016/j.psyneuen.2014.04.003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 8.4] [Reference Citation Analysis]
19 Guaraldi G, Stentarelli C, Zona S, Santoro A. HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs 2013;73:1431-50. [PMID: 24002702 DOI: 10.1007/s40265-013-0108-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
20 Ngala RA, Fianko K. Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis. Afr Health Sci 2013;13:1107-16. [PMID: 24940339 DOI: 10.4314/ahs.v13i4.35] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
21 Giannaki CD, Sakkas GK, Karatzaferi C, Hadjigeorgiou GM, Lavdas E, Kyriakides T, Koutedakis Y, Stefanidis I. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. BMC Nephrol. 2013;14:194. [PMID: 24024727 DOI: 10.1186/1471-2369-14-194] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 8.7] [Reference Citation Analysis]
22 Marreez YMAH. Incorporation of “Human Body Composition” Course in the Medical or Premedical Curriculum. Med Sci Educ 2013;23:196-200. [DOI: 10.1007/bf03341621] [Reference Citation Analysis]
23 Vu CN, Ruiz-Esponda R, Yang E, Chang E, Gillard B, Pownall HJ, Hoogeveen RC, Coraza I, Balasubramanyam A. Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients. Metabolism 2013;62:1014-20. [PMID: 23522788 DOI: 10.1016/j.metabol.2013.01.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
24 Denue BA, Alkali MB, Abjah AU, Kida IM, Ajayi B, Fate BZ. Changes in Lipid Profiles and Other Biochemical Parameters in HIV-1 Infected Patients Newly Commenced on HAART Regimen. Infect Dis (Auckl) 2013;6:7-14. [PMID: 24847172 DOI: 10.4137/IDRT.S10044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
25 Lange DC, Secemsky EA, Ho JE, Hsue PY. Manifestations, Mechanisms, and Treatment of HIV-Associated Cardiovascular Disease. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease 2013. [DOI: 10.1016/b978-1-4557-0101-8.00048-5] [Reference Citation Analysis]
26 Herbst KL. Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin 2012;33:155-72. [PMID: 22301856 DOI: 10.1038/aps.2011.153] [Cited by in Crossref: 92] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
27 Guaraldi G, Chiara S, Zona S, Bagni B. Anthropometry in the Assessment of HIV-Related Lipodystrophy. Handbook of Anthropometry 2012. [DOI: 10.1007/978-1-4419-1788-1_152] [Reference Citation Analysis]
28 Guaraldi G, Bonucci PL, De Fazio D. Comparison of Three Different Methods for Correction of HIV-Associated Facial Lipodystrophy. Advanced Surgical Facial Rejuvenation 2012. [DOI: 10.1007/978-3-642-17838-2_64] [Reference Citation Analysis]
29 Mcgee S. Cushing Syndrome. Evidence-Based Physical Diagnosis 2012. [DOI: 10.1016/b978-1-4377-2207-9.00013-6] [Reference Citation Analysis]
30 Ihenetu K, Mason D. Biochemical Manifestation of HIV Lipodystrophy Syndrome. Int J MCH AIDS 2012;1:92-101. [PMID: 27621962 DOI: 10.21106/ijma.6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Taylor SA, Grunfeld C, Schambelan M. Endocrine complications of HIV infection. Sande's HIV/AIDS Medicine 2012. [DOI: 10.1016/b978-1-4557-0695-2.00022-5] [Reference Citation Analysis]
32 Giannaki CD, Sakkas GK, Karatzaferi C, Hadjigeorgiou GM, Lavdas E, Liakopoulos V, Tsianas N, Koukoulis GN, Koutedakis Y, Stefanidis I. Evidence of increased muscle atrophy and impaired quality of life parameters in patients with uremic restless legs syndrome. PLoS One. 2011;6:e25180. [PMID: 21984901 DOI: 10.1371/journal.pone.0025180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 3.3] [Reference Citation Analysis]
33 Janiszewski PM, Ross R, Despres JP, Lemieux I, Orlando G, Carli F, Bagni P, Menozzi M, Zona S, Guaraldi G. Hypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional study. PLoS One 2011;6:e25032. [PMID: 21966404 DOI: 10.1371/journal.pone.0025032] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
34 Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl) 2011;3:69-79. [PMID: 22096409 DOI: 10.2147/HIV.S14561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
35 Guaraldi G, Fontdevila J, Christensen LH, Orlando G, Stentarelli C, Carli F, Zona S, de Santis G, Pedone A, De Fazio D, Bonucci P, Martínez E. Surgical correction of HIV-associated facial lipoatrophy. AIDS 2011;25:1-12. [PMID: 20975513 DOI: 10.1097/QAD.0b013e32833f1463] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
36 Brown TT, Patil SP, Jacobson LP, Margolick JB, Laffan AM, Godfrey RJ, Johnson JR, Johnson-Hill LM, Reynolds SM, Schwartz AR, Smith PL. Anthropometry in the prediction of sleep disordered breathing in HIV-positive and HIV-negative men. Antivir Ther 2010;15:651-9. [PMID: 20587858 DOI: 10.3851/IMP1572] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
37 Guaraldi G, Zona S. From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection. Clinical Lipidology 2010;5:583-593. [DOI: 10.2217/clp.10.32] [Reference Citation Analysis]
38 Morgan M, Bartlett B, Cockerell C, Cohen P. Cutaneous Manifestations of HIV Infection. Mucocutaneous Manifestations of Viral Diseases 2010. [DOI: 10.3109/9781420073133-15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Rao MN, Mulligan K, Schambelan M. HIV Infection and Diabetes. Principles of Diabetes Mellitus 2010. [DOI: 10.1007/978-0-387-09841-8_38] [Reference Citation Analysis]
40 ANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONS. Meyler's Side Effects of Antimicrobial Drugs 2010. [DOI: 10.1016/b978-0-444-53272-5.50006-6] [Reference Citation Analysis]
41 Guaraldi G. Facial Fat Hypertrophy in Patients Who Receive Autologous Fat Tissue Transfer. Autologous Fat Transfer 2010. [DOI: 10.1007/978-3-642-00473-5_55] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 Narciso P, Bucciardini R, Tozzi V, Bellagamba R, Ivanovic J, Giulianelli M, Scevola S, Palummieri A, Fragola V, Massella M, Fracasso L, De Vita R, Pierro P, Del Maestro A, Mirra M, Weimer L. Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. AIDS Res Hum Retroviruses 2009;25:979-87. [PMID: 19795984 DOI: 10.1089/aid.2009.0029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
43 Sakkas GK, Mulligan K, Dasilva M, Doyle JW, Khatami H, Schleich T, Kent-Braun JA, Schambelan M. Creatine fails to augment the benefits from resistance training in patients with HIV infection: a randomized, double-blind, placebo-controlled study. PLoS One 2009;4:e4605. [PMID: 19242554 DOI: 10.1371/journal.pone.0004605] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
44 Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, Wen MJ, Lee GA, Grunfeld C, Schambelan M. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009;94:1137-44. [PMID: 19174500 DOI: 10.1210/jc.2008-1588] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 6.6] [Reference Citation Analysis]
45 Sekhar RV, Balasubramanyam A. Special Patient Populations: HIV Patients. Clinical Lipidology 2009. [DOI: 10.1016/b978-141605469-6.50047-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Scevola D, Oberto L, Barbarini G, Barbaro G. Guidelines for the Prevention of Cardiovascular Risk in HIV-Infected Patients Treated with Antiretroviral Drugs. Cardiovascular Disease in AIDS 2009. [DOI: 10.1007/978-88-470-0761-1_17] [Reference Citation Analysis]
47 Rappersberger K. HIV/AIDS. Braun-Falco’s Dermatology 2009. [DOI: 10.1007/978-3-540-29316-3_22] [Reference Citation Analysis]
48 Miyasaki Y, Goetz M, Newton T. Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome. Hormones, Brain and Behavior 2009. [DOI: 10.1016/b978-008088783-8.00103-0] [Reference Citation Analysis]
49 ENDOCRINE AND METABOLIC ADVERSE EFFECTS OF NON-HORMONAL AND NON-METABOLIC DRUGS. Meyler's Side Effects of Endocrine and Metabolic Drugs 2009. [DOI: 10.1016/b978-0-444-53271-8.50011-9] [Reference Citation Analysis]
50 Blauvelt A. HIV Disease and AIDS. Clinical and Basic Immunodermatology. [DOI: 10.1007/978-1-84800-165-7_21] [Reference Citation Analysis]
51 Greenblatt R, Tien P. The Endocrine System. HIV and Aging 2008. [DOI: 10.3109/9781420065985-6] [Reference Citation Analysis]
52 Joy T, Keogh HM, Hadigan C, Dolan SE, Fitch K, Liebau J, Johnsen S, Lo J, Grinspoon SK. Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr. 2008;47:174-184. [PMID: 17971710 DOI: 10.1097/qai.0b013e31815b0792] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 3.0] [Reference Citation Analysis]
53 Guallar JP, Gallego-Escuredo JM, Domingo JC, Alegre M, Fontdevila J, Martínez E, Hammond EL, Domingo P, Giralt M, Villarroya F. Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy. AIDS 2008;22:575-84. [PMID: 18316998 DOI: 10.1097/QAD.0b013e3282f56b40] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
54 Leyes P, Martínez E, de Talló Forga M. Use of Diet, Nutritional Supplements and Exercise in HIV-Infected Patients Receiving Combination Antiretroviral Therapies: A Systematic Review. Antiviral Therapy 2008;13:149-160. [DOI: 10.1177/135965350801300208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
55 Ballestri S, Lonardo A, Carulli L, Ricchi M, Bertozzi L, De Santis G, Bondi M, Loria P. The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology. Hepatology 2008;47:361-2. [PMID: 18161705 DOI: 10.1002/hep.21977] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
56 Weinberg ME, Lo JC, Grunfeld C, Schambelan M. Endocrine Complications of HIV Infection. Global HIV/AIDS Medicine 2008. [DOI: 10.1016/b978-1-4160-2882-6.50031-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Karsegard V, Pichard C. Infection par le VIH. Traité de nutrition artificielle de l’adulte. [DOI: 10.1007/978-2-287-33475-7_75] [Reference Citation Analysis]
58 Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, Contos MJ, Shiffman ML, Stravitz RT, Sterling RK, Sanyal AJ. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007;46:1091-100. [PMID: 17610277 DOI: 10.1002/hep.21803] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
59 Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, Boden D, Galovich J, Tenner-Racz K, Racz P, Carrington M, Petropoulos C, Katinger H, Markowitz M. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 2007;81:11016-31. [PMID: 17686878 DOI: 10.1128/JVI.01340-07] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 5.8] [Reference Citation Analysis]
60 Lichtenstein K, Balasubramanyam A, Sekhar R, Freedland E. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther 2007;4:16. [PMID: 17634130 DOI: 10.1186/1742-6405-4-16] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
61 Wilson ME, Allred KF, Kordik EM, Jasper DK, Rosewell AN, Bisotti AJ. Gender-specific effects of HIV protease inhibitors on body mass in mice. AIDS Res Ther 2007;4:8. [PMID: 17472747 DOI: 10.1186/1742-6405-4-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
62 Cushing's Syndrome. Evidence-Based Physical Diagnosis 2007. [DOI: 10.1016/b978-141602898-7.50016-2] [Reference Citation Analysis]
63 Karen S, Witold R, Cholewińska G. Physiotherapy of patients with lipodystrophy associated with HAART. HIV & AIDS Review 2007;6:20-22. [DOI: 10.1016/s1730-1270(10)60037-9] [Reference Citation Analysis]
64 Hsue PY, Waters DD. Treatment of Cardiovascular Manifestations of HIV. Cardiovascular Therapeutics 2007. [DOI: 10.1016/b978-1-4160-3358-5.50054-1] [Reference Citation Analysis]
65 Meulenbelt J, Fijen J. Antiviral Agents. Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose 2007. [DOI: 10.1016/b978-0-7216-0693-4.50058-x] [Reference Citation Analysis]
66 Mansur C, Freitas RRD, Rabêlo FT, Mansur L, Rabêlo FT, Santiago FCM, Oliveira TD, Azevedo FQ. Redistribuição da gordura corporal induzida pelos inibidores de protease em pacientes com Aids. An Bras Dermatol 2006;81:S317-9. [DOI: 10.1590/s0365-05962006000900015] [Reference Citation Analysis]
67 Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42:562-571. [PMID: 16837863 DOI: 10.1097/01.qai.0000229996.75116.da] [Cited by in Crossref: 100] [Cited by in F6Publishing: 116] [Article Influence: 5.9] [Reference Citation Analysis]
68 Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol 2006;163:860-9. [PMID: 16524955 DOI: 10.1093/aje/kwj111] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 4.2] [Reference Citation Analysis]
69 Rao MN, Lee GA, Grunfeld C. Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors. Am J Infect Dis 2006;2:159-66. [PMID: 22162956 DOI: 10.3844/ajidsp.2006.159.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
70 Lee D, Patel P, Sachs J, Basinger S, Mathews WC, Barber RE. Psychometric properties of a lipodystrophy scale. AIDS Patient Care STDS 2006;20:30-5. [PMID: 16426153 DOI: 10.1089/apc.2006.20.30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
71 Scevola D, Di Matteo A, Giglio O, Uberti F. HIV Infection-Related Cachexia and Lipodystrophy. Cachexia and Wasting: A Modern Approach 2006. [DOI: 10.1007/978-88-470-0552-5_40] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
72 Protease inhibitors. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions 2006. [DOI: 10.1016/b0-44-451005-2/00773-7] [Reference Citation Analysis]
73 Scevola D, Barbarini G, Barbaro G. Guidelines for the Prevention of Cardiovascular Risk in HIV-Infected Patients Treated with Antiretroviral Drugs. Cardiovascular Disease in AIDS. [DOI: 10.1007/88-470-0358-x_14] [Reference Citation Analysis]
74 Bacchetti P, Gripshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, Saag M, Scherzer R, Shlipak M, Tien P. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-131. [PMID: 16186728 DOI: 10.1097/01.qai.0000182230.47819.aa] [Cited by in Crossref: 232] [Cited by in F6Publishing: 252] [Article Influence: 12.9] [Reference Citation Analysis]
75 Thoma-greber E. HIV/AIDS. Dermatologie und Venerologie. [DOI: 10.1007/3-540-26624-0_19] [Reference Citation Analysis]
76 Guaraldi G, Orlando G, De Fazio D, Lorenzi ID, Rottino A, Santis GD, Pedone A, Spaggiari A, Baccarani A, Borghi V, Esposito R. Comparison of Three Different Interventions for the Correction of HIV-Associated Facial Lipoatrophy: A Prospective Study. Antiviral Therapy 2005;10:753-759. [DOI: 10.1177/135965350501000606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
77 Worrell CJ. Metabolic complications of antiretroviral therapy in children. Textbook of Pediatric HIV Care 2005. [DOI: 10.1017/cbo9780511544798.023] [Reference Citation Analysis]
78 Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered Adipokine Response in Murine 3T3-F442A Adipocytes Treated with Protease Inhibitors and Nucleoside Reverse Transcriptase Inhibitors. Antiviral Therapy 2005;10:207-13. [DOI: 10.1177/135965350501000202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
79 Smit E, Semba RD, Pilibosian E, Vlahov D, Tun W, Purvis L, Tang AM. Body habitus in a cohort of HIV-seropositive and HIV-seronegative injection drug users. AIDS Patient Care STDS 2005;19:19-30. [PMID: 15665632 DOI: 10.1089/apc.2005.19.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
80 Antiretroviral Drugs to Treat Human Immunodeficiency Virus Infections. Antiviral Agents, Vaccines, and Immunotherapies 2004. [DOI: 10.1201/b14238-3] [Reference Citation Analysis]
81 Sekhar RV, Jahoor F, Pownall HJ, Ballantyne CM, Balasubramanyam A. Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Curr Atheroscler Rep 2004;6:173-9. [PMID: 15068741 DOI: 10.1007/s11883-004-0029-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
82 Lo JC, Mulligan K, Noor MA, Lee GA, Schwarz JM, Grunfeld C, Schambelan M. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis 2004;39:732-5. [PMID: 15356790 DOI: 10.1086/422725] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
83 Maher B, Lloyd J, Wilkins EG, Fraser WD, Back D, Park BK, Pirmohamed M. Lipodystrophy in Patients with HIV-1 Infection: Effect of Stopping Protease Inhibitors on Tnf-α and Tnf-Receptor Levels, and on Metabolic Parameters. Antiviral Therapy 2004;9:879-887. [DOI: 10.1177/135965350400900601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
84 Weale AR, Bailey M, Lear PA. The level of non-citation of articles within a journal as a measure of quality: a comparison to the impact factor. BMC Med Res Methodol 2004;4:14. [PMID: 15169549 DOI: 10.1186/1471-2288-4-14] [Cited by in Crossref: 95] [Cited by in F6Publishing: 103] [Article Influence: 5.0] [Reference Citation Analysis]
85 Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003;63:2555-74. [PMID: 14636077 DOI: 10.2165/00003495-200363230-00001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 3.5] [Reference Citation Analysis]
86 Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004;135:273-9. [PMID: 14738456 DOI: 10.1111/j.1365-2249.2004.02367.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
87 Gougeon M, Pénicaud L, Fromenty B, Leclercq P, Viard J, Capeau J. Adipocytes Targets and Actors in the Pathogenesis of HIV-Associated Lipodystrophy and Metabolic Alterations. Antiviral Therapy 2004;9:161-177. [DOI: 10.1177/135965350400900206] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
88 Tungsiripat-gerber M, Aberg JA. Gender-Specific Issues in the Metabolic Complications of HIV Disease and Its Treatment. Principles of Gender-Specific Medicine 2004. [DOI: 10.1016/b978-012440905-7/50359-5] [Reference Citation Analysis]
89 Thorner A, Rosenberg E. Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective. Drugs 2003;63:1325-37. [PMID: 12825959 DOI: 10.2165/00003495-200363130-00001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
90 Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41:1195-1211. [PMID: 12405866 DOI: 10.2165/00003088-200241140-00004] [Cited by in Crossref: 127] [Cited by in F6Publishing: 129] [Article Influence: 6.4] [Reference Citation Analysis]
91 Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M. Correlates of Risk of Adipose Tissue Alterations and Their Modifications over Time in HIV-1-Infected Women Treated with Antiretroviral Therapy. Antiviral Therapy 2003;8:347-354. [DOI: 10.1177/135965350300800412] [Reference Citation Analysis]
92 Ben-Romano R, Rudich A, Török D, Vanounou S, Riesenberg K, Schlaeffer F, Klip A, Bashan N. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003;17:23-32. [PMID: 12478066 DOI: 10.1097/00002030-200301030-00005] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 3.2] [Reference Citation Analysis]
93 Green ML. Evaluation and management of dyslipidemia in patients with HIV infection. J Gen Intern Med 2002;17:797-810. [PMID: 12390557 DOI: 10.1046/j.1525-1497.2002.20201.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
94 Deeb F, Cheskin L. OBESITY | Fat Distribution. Encyclopedia of Food Sciences and Nutrition 2003. [DOI: 10.1016/b0-12-227055-x/00851-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Shevitz AH. Epidemiology of Fat Redistribution in HIV. Lipodystrophy Syndrome in HIV 2003. [DOI: 10.1007/978-1-4615-0471-9_2] [Reference Citation Analysis]
96 Husak R, Orfanos CE. HIV infection and AIDS: present status of antiretroviral therapy. European Handbook of Dermatological Treatments 2003. [DOI: 10.1007/978-3-662-07131-1_41] [Reference Citation Analysis]
97 Shikuma CM, Souza S, Shiramizu B. Pathogenesis of HIV Lipodystrophy. Lipodystrophy Syndrome in HIV 2003. [DOI: 10.1007/978-1-4615-0471-9_7] [Reference Citation Analysis]
98 Khatami H, Mulligan K. Body Composition in HIV Lipodystrophy. Lipodystrophy Syndrome in HIV 2003. [DOI: 10.1007/978-1-4615-0471-9_3] [Reference Citation Analysis]
99 Wanke CA. Potential Therapies for the HIV-Associated Lipodystrophy Syndrome. Lipodystrophy Syndrome in HIV 2003. [DOI: 10.1007/978-1-4615-0471-9_10] [Reference Citation Analysis]
100 Wanke C, Polsky B, Kotler D. Guidelines for using body composition measurement in patients with human immunodeficiency virus infection. AIDS Patient Care STDS 2002;16:375-88. [PMID: 12227988 DOI: 10.1089/10872910260196404] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
101 Gervasoni C, Ridolfo AL, Rovati L, Vaccarezza M, Carsana L, Galli M. Maintenance of breast size reduction after mastoplasty and switch to a protease inhibitor-sparing regimen in an HIV-positive woman with highly active antiretroviral therapy-associated massive breast enlargement. AIDS Patient Care STDS 2002;16:307-11. [PMID: 12194727 DOI: 10.1089/108729102320231135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
102 García-Benayas T, Blanco F, Gómez-Viera JM, Barrios A, Soriano V, González-Lahoz J. Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy. AIDS 2002;16:1087-9. [PMID: 11953483 DOI: 10.1097/00002030-200205030-00023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
103 le Roux CW, Beckles MA, Besser GM, Pinching AJ, Davison AG. Cushing's syndrome secondary to inhaled corticosteroids mimicking HIV-associated lipodystrophy. HIV Med 2001;2:133-5. [PMID: 11737390 DOI: 10.1046/j.1468-1293.2001.00058.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
104 Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002;155:760-70. [PMID: 11943695 DOI: 10.1093/aje/155.8.760] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 1.7] [Reference Citation Analysis]
105 Grunfeld C. HIV protease inhibitors and glucose metabolism. AIDS 2002;16:925-6. [PMID: 11919495 DOI: 10.1097/00002030-200204120-00013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
106 Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001;2:174-80. [PMID: 11737398 DOI: 10.1046/j.1468-1293.2001.00073.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 3.0] [Reference Citation Analysis]
107 Roche R, Poizot-Martin I, Yazidi CM, Compe E, Gastaut JA, Torresani J, Planells R. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 2002;16:13-20. [PMID: 11741158 DOI: 10.1097/00002030-200201040-00003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 2.5] [Reference Citation Analysis]
108 Orfanos CE, Garbe C. HIV-Infektion und Kaposi-Sarkom. Therapie der Hautkrankheiten 2002. [DOI: 10.1007/978-3-642-56219-8_44] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
109 Schooley RT, Benson CA. Pathogenesis and Clinical Manifestations of HIV-1 Infection. Clinical Approach to Infection in the Compromised Host 2002. [DOI: 10.1007/0-306-47527-8_12] [Reference Citation Analysis]
110 Roubenoff R. Exercise and HIV Infection. Nutrition in Clinical Care 2001;3:230-6. [DOI: 10.1046/j.1523-5408.2000.00057.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
111 Brambilla P, Bricalli D, Sala N, Renzetti F, Manzoni P, Vanzulli A, Chiumello G, di Natale B, Viganò A. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy. AIDS 2001;15:2415-22. [PMID: 11740192 DOI: 10.1097/00002030-200112070-00009] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 3.1] [Reference Citation Analysis]
112 Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS 2001;15:1917-30. [PMID: 11600819 DOI: 10.1097/00002030-200110190-00003] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 2.8] [Reference Citation Analysis]
113 Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube MP. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001;15:2001-10. [PMID: 11600829 DOI: 10.1097/00002030-200110190-00013] [Cited by in Crossref: 78] [Cited by in F6Publishing: 84] [Article Influence: 3.5] [Reference Citation Analysis]
114 Matheny SC. Clinical dilemmas in palliative care for HIV infection. J R Soc Med 2001;94:449-51. [PMID: 11535746 DOI: 10.1177/014107680109400908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
115 Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA; PIILR Study Group. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811-22. [PMID: 11579243 DOI: 10.1097/00002030-200109280-00010] [Cited by in Crossref: 132] [Cited by in F6Publishing: 138] [Article Influence: 6.0] [Reference Citation Analysis]
116 Keithley JK. CONTINUING EDUCATION OFFERING. Journal of the Association of Nurses in AIDS Care 2001;12:67-74. [DOI: 10.1016/s1055-3290(06)60160-x] [Reference Citation Analysis]
117 Polsky B, Kotler D, Steinhart C. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDS 2001;15:411-23. [PMID: 11522215 DOI: 10.1089/108729101316914412] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 1.9] [Reference Citation Analysis]
118 Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, Rhodes PH, Wood KC, Holmberg SD; HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-98. [PMID: 11504960 DOI: 10.1097/00002030-200107270-00008] [Cited by in Crossref: 326] [Cited by in F6Publishing: 282] [Article Influence: 14.8] [Reference Citation Analysis]
119 Schrooten W, Colebunders R, Youle M, Molenberghs G, Dedes N, Koitz G, Finazzi R, de Mey I, Florence E, Dreezen C; Eurosupport Study Group. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 2001;15:1019-23. [PMID: 11399984 DOI: 10.1097/00002030-200105250-00010] [Cited by in Crossref: 81] [Cited by in F6Publishing: 89] [Article Influence: 3.7] [Reference Citation Analysis]
120 Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-8. [PMID: 11399973 DOI: 10.1097/00002030-200105040-00001] [Cited by in Crossref: 238] [Cited by in F6Publishing: 249] [Article Influence: 10.8] [Reference Citation Analysis]
121 van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, Danner SA; Prometheus study group. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001;15:847-55. [PMID: 11399957 DOI: 10.1097/00002030-200105040-00005] [Cited by in Crossref: 121] [Cited by in F6Publishing: 126] [Article Influence: 5.5] [Reference Citation Analysis]
122 Chastain MA, Chastain JB, Coleman WP. HIV Lipodystrophy. Dermatologic Surgery 2001;27:497-500. [DOI: 10.1097/00042728-200105000-00017] [Reference Citation Analysis]
123 Tebas P, Henry K, Nease R, Murphy R, Phair J, Powderly WG. Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy. AIDS 2001;15:591-9. [PMID: 11316996 DOI: 10.1097/00002030-200103300-00008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
124 Urso R, Gentile M. Are 'buffalo hump' syndrome, Madelung's disease and multiple symmetrical lipomatosis variants of the same dysmetabolism? AIDS 2001;15:290-1. [PMID: 11216947 DOI: 10.1097/00002030-200101260-00028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
125 Mercié P, Viallard JF, Thiébaut R, Faure I, Rispal P, Leng B, Pellegrin JL. Efavirenz-associated breast hypertrophy in HIV-infection patients. AIDS 2001;15:126-9. [PMID: 11192857 DOI: 10.1097/00002030-200101050-00021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.2] [Reference Citation Analysis]
126 del Valle Gutiérrez F, Gómez Rodrigo F. Lipodistrofia y alteraciones metabólicas en pacientes infectados por el virus de la inmunodeficiencia humana tratados con inhibidores de la proteasa. Clínica e Investigación en Arteriosclerosis 2001;13:254-9. [DOI: 10.1016/s0214-9168(01)78809-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
127 John M, Nolan D, Mallal S. Antiretroviral Therapy and the Lipodystrophy Syndrome. Antiviral Therapy 2001;6:9-20. [DOI: 10.1177/135965350100600102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
128 Weiel JE, Lenhard JM. Chapter 13. In vitro and in vivo approaches to studying antiretroviral therapy (ART)-induced metabolic complications. Annual Reports in Medicinal Chemistry 2001. [DOI: 10.1016/s0065-7743(01)36053-0] [Reference Citation Analysis]
129 Marlink R, Kao H, Hsieh E; "Giving Voice to a Silent Epidemic" Working Group. Clinical care issues for women living with HIV and AIDS in the United States. AIDS Res Hum Retroviruses 2001;17:1-33. [PMID: 11177380 DOI: 10.1089/088922201750056753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
130 HIV-Arbeitskreis Südwest, Deutsche AIDS-Hilfe e.V.. Therapie. HIV und AIDS 2001. [DOI: 10.1007/978-3-642-97898-2_3] [Reference Citation Analysis]
131 Mildvan D. Rationale and Strategies for Antiretroviral Therapy in HIV-1 Infection. Atlas of AIDS 2001. [DOI: 10.1007/978-1-4757-4549-8_19] [Reference Citation Analysis]
132 Ceballos-Salobreña A, Gaitán-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDS 2000;14:627-35. [PMID: 11119429 DOI: 10.1089/10872910050206540] [Cited by in Crossref: 92] [Cited by in F6Publishing: 97] [Article Influence: 4.0] [Reference Citation Analysis]
133 Kanmaz TJ, Lee NJ. Significant Toxicities Associated with Antiretroviral Therapy. Journal of Pharmacy Practice 2000;13:457-474. [DOI: 10.1106/2uu8-8jjd-uhru-c14r] [Reference Citation Analysis]
134 Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf. 2000;23:57-76. [PMID: 10915032 DOI: 10.2165/00002018-200023010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000;23:57-76. [PMID: 10915032 DOI: 10.2165/00002018-200023010-00004] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 3.3] [Reference Citation Analysis]
136 Ridolfo AL, Gervasoni C, Bini T, Galli M. Body habitus alterations in HIV-infected women treated with combined antiretroviral therapy. AIDS Patient Care STDS 2000;14:595-601. [PMID: 11155901 DOI: 10.1089/10872910050193770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
137 Muir Bowers J. Lipodystrophy. Nutrition and AIDS, Second Edition 2000. [DOI: 10.1201/9781420042290.ch10] [Reference Citation Analysis]
138 Hatano H, Miller KD, Yoder CP, Yanovski JA, Sebring NG, Jones EC, Davey RT Jr. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000;14:1935-42. [PMID: 10997397 DOI: 10.1097/00002030-200009080-00008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 2.4] [Reference Citation Analysis]
139 Roudiére L, Viard JP. Osteonecrosis of the hip, lipodystrophy and antiretroviral treatment. AIDS 2000;14:2056. [PMID: 10997415 DOI: 10.1097/00002030-200009080-00026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
140 Abourjaily P, Small F. HIV‐Associated Disorders in Fat Distribution and Lipid Metabolism. Nutrition in Clinical Care 2000;3:237-243. [DOI: 10.1046/j.1523-5408.2000.00058.x] [Reference Citation Analysis]
141 Raulin J. Lipids and retroviruses. Lipids 2000;35:123-30. [PMID: 10757541 DOI: 10.1007/BF02664760] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
142 Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, González-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12. [PMID: 10839588 DOI: 10.1097/00002030-200005050-00006] [Cited by in Crossref: 120] [Cited by in F6Publishing: 121] [Article Influence: 5.2] [Reference Citation Analysis]
143 Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-7. [PMID: 10770534 DOI: 10.1097/00002030-200003100-00005] [Cited by in Crossref: 389] [Cited by in F6Publishing: 402] [Article Influence: 16.9] [Reference Citation Analysis]
144 Cohen CJ, Piliero PJ, Pile OH. Increasing Treatment Adherence in the Correctional Setting: Current Efforts to Simplify Protease Inhibitor Dosing Regimens. Journal of Correctional Health Care 2000;7:61-90. [DOI: 10.1177/107834580000700103] [Reference Citation Analysis]
145 Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999;58:1165-203. [PMID: 10651394 DOI: 10.2165/00003495-199958060-00011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 2.8] [Reference Citation Analysis]
146 Behrens G, Dejam A, Schmidt H, Balks H, Brabant G, Körner T, Stoll M, Schmidt RE. Beeinflussung der Glukosetoleranz, B-Zell-Funktion und des Lipid Metabolismus bei HIV-1 infizierten Patienten unter der Therapie mit Proteaseinhibitoren. HIV-Infekt 2000. [DOI: 10.1007/978-3-642-59683-4_67] [Reference Citation Analysis]
147 Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS 2000;14:13-8. [PMID: 12240878 DOI: 10.1089/108729100318091] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.2] [Reference Citation Analysis]
148 Reiss P, de Jong M. Antiviral drugs. Side Effects of Drugs Annual 2000. [DOI: 10.1016/s0378-6080(00)80035-5] [Reference Citation Analysis]
149 Bork K. Unerwünschte Arzneimittelreaktionen, Pathogenese, Klinik, Therapie. HIV-Infekt 2000. [DOI: 10.1007/978-3-642-59683-4_65] [Reference Citation Analysis]
150 Strobel M, Muller P, Claudel P. Complete reversibility of severe nucleoside-induced lipodystrophy. AIDS 1999;13:2606-7. [PMID: 10630538 DOI: 10.1097/00002030-199912240-00023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
151 Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505. [PMID: 10630518 DOI: 10.1097/00002030-199912240-00002] [Cited by in Crossref: 295] [Cited by in F6Publishing: 253] [Article Influence: 12.3] [Reference Citation Analysis]
152 García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. AIDS 1999;13:2377-88. [PMID: 10597779 DOI: 10.1097/00002030-199912030-00009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 1.4] [Reference Citation Analysis]
153 Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999;13:2251-60. [PMID: 10563710 DOI: 10.1097/00002030-199911120-00007] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 4.3] [Reference Citation Analysis]
154 Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13:2099-103. [PMID: 10546863 DOI: 10.1097/00002030-199910220-00013] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 4.0] [Reference Citation Analysis]
155 Mercié P, Faure I, Viallard J, Leng B, Pellegrin I. Lipodystrophie sous inhibiteurs nucléosidiques de la transcriptase inverse: trois cas. Médecine et Maladies Infectieuses 1999;29:648-649. [DOI: 10.1016/s0399-077x(00)87144-9] [Reference Citation Analysis]
156 Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, Cryer PE, Powderly WG. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999;21:209-16. [PMID: 10421244 DOI: 10.1097/00126334-199907010-00005] [Cited by in Crossref: 107] [Cited by in F6Publishing: 111] [Article Influence: 4.5] [Reference Citation Analysis]
157 Roubenoff R, Weiss L, McDermott A, Heflin T, Cloutier GJ, Wood M, Gorbach S. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999;13:1373-5. [PMID: 10449291 DOI: 10.1097/00002030-199907300-00015] [Cited by in Crossref: 115] [Cited by in F6Publishing: 118] [Article Influence: 4.8] [Reference Citation Analysis]
158 Shevitz AH, Knox TA, Spiegelman D, Roubenoff R, Gorbach SL, Skolnik PR. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999;13:1351-7. [PMID: 10449288 DOI: 10.1097/00002030-199907300-00012] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 3.3] [Reference Citation Analysis]
159 Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 1999;13:1287-93. [PMID: 10449280 DOI: 10.1097/00002030-199907300-00004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 2.2] [Reference Citation Analysis]
160 Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, Stoll M, Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70. [PMID: 10416516 DOI: 10.1097/00002030-199907090-00001] [Cited by in Crossref: 352] [Cited by in F6Publishing: 373] [Article Influence: 14.7] [Reference Citation Analysis]
161 Moyle GJ, Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Saf 1999;20:299-321. [PMID: 10230580 DOI: 10.2165/00002018-199920040-00002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 1.2] [Reference Citation Analysis]
162 Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10. [PMID: 10357379 DOI: 10.1097/00002030-199905070-00009] [Cited by in Crossref: 250] [Cited by in F6Publishing: 254] [Article Influence: 10.4] [Reference Citation Analysis]
163 Mann M, Piazza-Hepp T, Koller E, Struble K, Murray J. Unusual distributions of body fat in AIDS patients: a review of adverse events reported to the Food and Drug Administration. AIDS Patient Care STDS 1999;13:287-95. [PMID: 10356808 DOI: 10.1089/apc.1999.13.287] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
164 Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999;13:F35-43. [PMID: 10397555 DOI: 10.1097/00002030-199904160-00001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 324] [Article Influence: 13.3] [Reference Citation Analysis]
165 Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999;13:735-7. [PMID: 10397574 DOI: 10.1097/00002030-199904160-00020] [Cited by in Crossref: 147] [Cited by in F6Publishing: 154] [Article Influence: 6.1] [Reference Citation Analysis]
166 Schmidt HH, Behrens G, Genschel J, Stoll M, Dejam A, Haas R, Manns MP, Schmidt RE. Lipid Evaluation in HIV-1-Positive Patients Treated with Protease Inhibitors. Antiviral Therapy 1999;4:163-170. [DOI: 10.1177/135965359900400305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
167 Castetbon K, Malvy D. Dénutrition chez les adultes infectés par le virus de l'immunodéficience humaine. Nutrition Clinique et Métabolisme 1999;13:17-24. [DOI: 10.1016/s0985-0562(99)80004-1] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
168 Roubenoff R, McDermott A, Weiss L, Suri J, Wood M, Bloch R, Gorbach S. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 1999;13:231-9. [PMID: 10202829 DOI: 10.1097/00002030-199902040-00011] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 3.3] [Reference Citation Analysis]
169 Ockenga J, Manns MP. The impact of body composition analysis in HIV-infected patients: quantifying therapeutic effects. AIDS 1999;13:279-80. [PMID: 10202835 DOI: 10.1097/00002030-199902040-00017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
170 Izopet J, Sailler L, Sandres K, Pasquier C, Bonnet E, Aquilina C, Puel J, Massip P, Marchou B. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations. J Med Virol 1999;57:163-168. [DOI: 10.1002/(sici)1096-9071(199902)57:2<163::aid-jmv13>3.0.co;2-a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
171 Schechter M, Struchiner CJ, Harrison LH. Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better? AIDS 1999;13:97-102. [PMID: 10207550 DOI: 10.1097/00002030-199901140-00013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
172 Reiss P, Jong MD. Antiviral drugs. Side Effects of Drugs Annual 1999. [DOI: 10.1016/s0378-6080(99)80034-8] [Reference Citation Analysis]
173 Kahn JO. Initial Treatment for HIV Infection. Antiviral Chemotherapy 5 1999. [DOI: 10.1007/978-1-4615-4743-3_22] [Reference Citation Analysis]
174 Ho TT, Chan KC, Wong KH, Lee SS. Indinavir-associated facial lipodystrophy in HIV-infected patients. AIDS Patient Care STDS 1999;13:11-6. [PMID: 11362080 DOI: 10.1089/apc.1999.13.11] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
175 Carlton S, Evans T, Tyring SK. New antiviral agents for dermatologic disease. Seminars in Cutaneous Medicine and Surgery 1998;17:243-255. [DOI: 10.1016/s1085-5629(98)80020-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
176 Martínez E, Casamitjana R, Conget I, Gatell JM. Protease inhibitor-associated hyperinsulinaemia. AIDS 1998;12:2077-9. [PMID: 9814880 DOI: 10.1097/00002030-199815000-00023] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
177 Eriksson U, Opravil M, Amann FW, Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS 1998;12:2079-80. [PMID: 9814881 DOI: 10.1097/00002030-199815000-00024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.1] [Reference Citation Analysis]
178 Kaufmann GR, Duncombe C, Cunningham P, Beveridge A, Carr A, Sayer D, French M, Cooper DA. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS 1998;12:1625-30. [PMID: 9764781 DOI: 10.1097/00002030-199813000-00009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 1.6] [Reference Citation Analysis]